NREP
NEW REPRESENTATIVE AT IB RECEIVED
05/11/2024
Back to search
Official data from USPTO
JOONGKYEOM ANTIBODY THERAPY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
05/11/2024
Trademark type
Combined
Nice classes
5, 35, 42
Filing date
11/16/2021
Registration date
04/04/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/04/2023
Last transaction
04/04/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
03
Owner location
KR
Examiner
CHANG, BETTY
Law office
M60
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording "JOONGKYEOM" stacked above the wording "ANTIBODY THERAPY", wherein an infinity symbol represents the letters "OO", all to the left of a stylized letter "X" and its shadow.
Holders and representatives
Holders
JOONGKYEOM Co., Ltd.
Representatives
Ziwen Zhu Locke Lord LLP
Technical classification
Nice Classes
Class 5Class 35Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Preparations of microorganisms for medical use; bacterial preparations for medical and veterinary use; diagnostic preparations for medical and veterinary use; cultures of microorganisms for medical and veterinary use; preparations of microorganisms for medical and veterinary use; bacteriological preparations for medical and veterinary use; biological preparations for medical purposes; diagnostic agents for medical use; medicinal diagnostic reagents; pharmaceutical preparations for diagnosis; preparations for diagnosing antibodies; pharmaceutical preparations for the treatment of antibodies
Class 35
Wholesale store services featuring microorganisms for medical purposes; retail store services featuring microorganisms for medical purposes; wholesale store services featuring bacterial preparations for medical and veterinary use; retail store services featuring bacterial preparations for medical and veterinary use; wholesale store services featuring diagnostic preparations for medical and veterinary use; retail store services featuring diagnostic preparations for medical and veterinary use; business intermediary services relating to the matching of parties for purchase and sale of drugs for medical purposes; wholesale store services featuring drugs for medical purposes; retail store services featuring drugs for medical purposes; wholesale store services featuring medical preparations for diagnosing antibodies; retail store services featuring medical preparations for diagnosing antibodies; wholesale store services featuring medicinal diagnostic reagents; retail store services featuring medicinal diagnostic reagents; business intermediary services relating to the matching of parties for purchase and sale of medicinal diagnostic reagents; wholesale store services featuring pharmaceutical preparations for diagnosis; retail store services featuring pharmaceutical preparations for diagnosis; business merchandising display services; wholesale store services featuring pharmaceutical preparations for the treatment of antibodies; retail store services featuring pharmaceutical preparations for the treatment of antibodies; sales agency servicesindependent sale representatives for pharmaceutical preparations for the treatment of antibodies
Class 42
Research and development of vaccines and medicines; advisory services relating to biotechnology; research relating to biotechnology; consulting services in the fields of biotechnology; biological research; medical research in the field of crude drugs; biochemical analysis; biochemistry research services; research on adult diseases; research relating to bacteriology; research services in the fields of cancerous diseases; development of pharmaceuticals; research relating to pharmaceuticals; advisory services relating to development of pharmaceuticals; pharmaceutical products evaluation; consultancy pertaining to pharmacology; research in the field of gene analysis; genetic research; research relating to medical products; medical research services
Publications
History of USPTO decisions and trademark events.
29 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/14/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/24/2023
FIMP
FINAL DISPOSITION PROCESSED
07/24/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/04/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/04/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
04/04/2023
GPNX
NOTIFICATION PROCESSED BY IB
01/25/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/17/2023
PUBO
PUBLISHED FOR OPPOSITION
01/17/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/04/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/04/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/28/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/15/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/14/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/13/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/13/2022
RFNP
REFUSAL PROCESSED BY IB
11/14/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
10/22/2022
RFRR
REFUSAL PROCESSED BY MPU
10/21/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/31/2022
CNRT
NON-FINAL ACTION WRITTEN
08/30/2022
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
08/30/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/28/2022
CNRT
NON-FINAL ACTION WRITTEN
08/27/2022
DOCK
ASSIGNED TO EXAMINER
08/27/2022
MAFR
APPLICATION FILING RECEIPT MAILED
02/19/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/15/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/10/2022
Continuous trademark protection
Get notified about every new filing that threatens JOONGKYEOM ANTIBODY THERAPY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.